The AIM-HI Accelerator Fund is proud to announce the appointment of Silas Deane, Vice President at Tyler Technologies, to its Board of Directors. Mr. Deane, a long-time supporter and advocate of innovative cancer research, brings a wealth of expertise in technology, healthcare, and business development. His leadership and entrepreneurial background mark a significant addition to AIM-HI’s mission of advancing oncology-focused startups and accelerating breakthroughs in cancer treatments.
With a diverse career, Silas Deane has played pivotal roles in various sectors. His previous experience includes working with U.S. Senator and Vice President Al Gore, Jr., as well as leadership positions at Tyler Technologies (NYSE: TYL), VendEngine, Inc., Logic Media Group, and the International Microelectronics Packaging Society.
In 2011, Silas Deane founded VendEngine, Inc., a company that revolutionized public safety systems by providing real-time data and transparency while supporting incarcerated individuals and their families. The company was acquired by Tyler Technologies in 2021 for $84 million, where Silas Deane now serves as Vice President, focusing on driving innovation and growth in public safety technology. Recognized by Deloitte & Touche in 2020 as one of North America’s Top 300 Fastest Growing Technology Companies, Mr. Deane’s entrepreneurial achievements will now fuel AIM-HI’s mission to foster innovation in oncology startups and help bring cancer treatments from lab to clinic.
“As cancer research advances, it’s becoming clear that innovation and early-stage investment are crucial to achieving real breakthroughs,” Silas Deane remarked. “I’m honored to join AIM-HI’s Board and excited to contribute to their efforts in supporting pioneering companies that are poised to make a real difference in cancer treatment.”
“Silas’s track record of driving technology and business innovation makes him a perfect fit for our Board,” said Dr. Sujuan Ba, CEO and Co-Founder of the AIM-HI Accelerator Fund. “We’re looking forward to working together to propel our mission of accelerating promising cancer treatments and providing vital support to oncology startups.”
